With a booth to reflect SHL’s Scandinavian roots, SHL created excitement at PDA about the new Penny Pen injector, as well as the Molly 2.25 auto injector and Alubena, a programme dedicated to connectivity based innovations for drug delivery systems.
The 3mL multi-dose disposable pen injector Penny garnered attention as it is a device designed based on well-studied user behaviors in the diabetes area and has had outstanding test results across the board.
The device offers several advantages, including variable and/or set doses and is designed for large-scale manufacturing. Penny also allows full freedom to operate (FTO) and a short time to market if a pre-configured device is chosen.
Molly 2.25 auto injector also gained attention as its predecessor, the Molly auto injector with a standard 1mL PFS, is a well-known industry benchmark for its ultra-compact design and simple two-step operation.
SHL Commercial Operations and Business Development for Europe executive vice-president Mats Persson said: "We are very excited by the number of inquiries made towards the various devices and new technologies we introduced this year.
"In addition, we were fortunate to have had the chance to engage with so many customers in deeper conversations to better understand their needs and the upcoming industry trends.
"Continuously learning and innovating to anticipate and meet customer needs is core to our beliefs, which is why we invest so much into critical industry events like the PDA."
Another major trending topic this year was connectivity. SHL introduced for the first time Alubena, a programme dedicated to connectivity based innovations for drug delivery systems with the goal of enhancing patient adherence.
The recording unit combined with the auto injector device transfers injection data to a smartphone via Bluetooth, then to a secure cloud where injection data can be safely retrieved by smart devices, and customised information can be provided to different stakeholders such as patients, relatives and healthcare professionals.
The Alubena programme will provide highly customisable and connectivity solutions for drug delivery devices to provide means for enhancing patient adherence and contributing to healthy outcomes.